Vídeos de câncer de mama
645 vídeos de câncer de mama de sociedades, congressos e centros de oncologia (22 em português). Lista atualizada em 20/11/2026; abaixo, os mais recentes.
Assistir ao canal Mama no OncoTV
Câncer de mama e vulnerabilidades sociais: como reduzir inequidades?SBOC · 19/11/2026 · 23:22
Closing off #ESMO26 highlights with #BreastCancer with Dr. Javier CortésOncology Brothers · 19/11/2026 · 2:15 · apoio da indústria
The role of imaging before and after neoadjuvant therapy in breast cancerVJOncology · 18/11/2026 · 1:06 · apoio da indústria
Dr Ligibel on Quality of Life Gains From the BWEL Weight Loss Program in Breast CancerTargeted Oncology · 17/11/2026 · 8:42 · apoio da indústria
Do congresso à prática | PÓS-ESMO GBECAM 2026GBECAM · 12/11/2026 · 1:49:25
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO...ASCO Podcasts · 29/10/2026 · 14:20
ESMO Breast Cancer 2027: New ideas and new collaborationsESMO · 02/10/2026 · 1:34
NCCN 2027 Breast Cancer Congress: Connect with Experts & Gain New Insights to Implement in PracticeNCCN · 24/09/2026 · 1:38
Conferência Brasileira de Câncer de Mama Best of SABCS - Edição 2026LACOG · 13/08/2026 · 2:42
ASCO 2026: Breast cancer overviewecancer · 16/07/2026 · 4:58 · apoio da indústria
20 Year follow-up EORTC breast cancer trial 22922/10925 with Philip Poortmans and Orit Kaidar-PersonEORTC · 30/06/2026 · 1:53
First Look at Iza-bren in TNBC: Dr. Megan Kruse on Top ASCO26 ResearchASCO · 02/06/2026 · 1:41
Dr Callahan on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast CancerOncLive · 24/04/2026 · 1:58 · apoio da indústria
066: Running for Research: Katie Rabinowitz Seeks to Live Well with Metastatic Breast CancerAACR · 04/03/2026 · 32:57
Ruxolitinib plus CDK4/6 inhibitor abemaciclib in previously treated myelofibrosis: Phase I resultsVJHemOnc · 23/01/2026 · 3:26 · apoio da indústria
II Simpósio Câncer de Mama e Saúde da População Negra: Passado, Presente e FuturoINCA · 19/03/2025 · 2:53:50
🎀 Outubro Rosa: informação também é prevenção.SBOC · 13/10/2026 · 1:24
ESMO 2026 Breast Cancer Highlights: NATALEE, postMONARCH, TROPION-Breast02, INSPIRE-LMOncology Brothers · 19/11/2026 · 24:06 · apoio da indústria
Comparing CEM and MRI for assessing treatment responses in breast cancerVJOncology · 18/11/2026 · 1:56 · apoio da indústria
Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast CancerTargeted Oncology · 06/10/2026 · 11:54 · apoio da indústria
Estudo JCOG1204A1: ctDNA pode antecipar a recidiva em cerca de 7 meses? | GBECAM na ESMO 2026GBECAM · 12/11/2026 · 2:55
JCO PO Article Insights: Tumor-informed ctDNA in Early Triple Negative Breast CancerASCO Podcasts · 28/10/2026 · 7:56
ESMO Congress 2026: Breast cancer, advanced stage Track – Programme HighlightsESMO · 31/03/2026 · 1:15
Attend the NCCN 2026 Breast Cancer Congress for Clinical Updates and Expert InsightsNCCN · 02/10/2025 · 2:06
Conferência Brasileira de Câncer de Mama Best of SABCS - Edição 2025LACOG · 05/11/2025 · 2:00
Adagloxad simolenin and OBI-821 shows no survival benefit compared to standard of care in triple...ecancer · 16/07/2026 · 10:02 · apoio da indústria
Betty | EORTC Clinical Study ParticipantEORTC · 04/02/2026 · 3:13
2026 Oncology Coding UpdatesASCO · 23/12/2025 · 43:22
Dr Moslehi on the Role of Cardio-Oncology in Breast Cancer Treatment Decision-MakingOncLive · 13/04/2026 · 2:16 · apoio da indústria
Michelle Anderson-Benjamin: Living With Stage IV Triple-Negative Breast CancerAACR · 17/09/2025 · 4:58
I Simpósio Câncer de Mama e Saúde da População NegraINCA · 13/03/2024 · 4:41:38
Tumores MamáriosSBOC · 24/06/2026 · 2:57
PIK3CA Mutation Option in Hormone Receptor Positive Breast Cancer - Deeper Dive in INAVO120 TrialOncology Brothers · 02/10/2026 · 31:48 · apoio da indústria
Omitting axillary surgery after complete response to neoadjuvant therapyVJOncology · 18/11/2026 · 1:57 · apoio da indústria
Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic TestingTargeted Oncology · 15/09/2026 · 23:29 · apoio da indústria
Estudo HORIZON-Breast06: 73% de redução no risco de progressão ou morte | GBECAM na ESMO 2026GBECAM · 12/11/2026 · 4:10
pCR Rates and Predictors With THP in HER2-Positive Breast Cancer: EA1181/CompassHER2 pCRASCO Podcasts · 08/10/2026 · 21:26
ESMO Congress 2025 Breast cancer, early stage Track – Programme HighlightsESMO · 16/07/2025 · 1:23
You Are Invited to the NCCN 2025 Breast Cancer CongressNCCN · 30/10/2024 · 1:31
Weight loss intervention improves quality of life in breast cancer survivorsecancer · 16/07/2026 · 3:43 · apoio da indústria